Levacetylleucine
This modified amino acid derivative has been investigated for the treatment of rare inherited neurological conditions called neuronal ceroid lipofuscinoses (Batten disease), where it may help stabilize cell membranes and reduce neurodegeneration. Research into its therapeutic potential for these devastating childhood diseases is ongoing.
Moleküler Ağırlık
173,2100 g/mol
LogP
0,50
TPSA
66,40 Ų
Lipinski RO5
Geçer
Etki Mekanizması
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.
2D Yapı
Cite this structure
Embed this structure
SMILES
CC(=O)N[C@@H](CC(C)C)C(=O)O
InChI
InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m0/s1
Molecular Formula
C8H15NO3
HBD / HBA
2 / 3
Döndürülebilir Bağlar
4
Ağır Atomlar
12
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
This modified amino acid derivative has been investigated for the treatment of rare inherited neurological conditions called neuronal ceroid lipofuscinoses (Batten disease), where it may help stabilize cell membranes and reduce neurodegeneration. Research into its therapeutic potential for these devastating childhood diseases is ongoing.
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway of cholesterol biosynthesis. This reduces intracellular cholesterol, upregulates LDL receptor expression, and lowers circulating LDL cholesterol.
Yes, Levacetylleucine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL56021. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 70912. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="levacetylleucine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/levacetylleucine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/levacetylleucine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/levacetylleucine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="levacetylleucine"></drugfyi-drug>